Table 5.

Treatment Regimen Sequence in Metastatic^a Unens by Differentiation

Treatment Sequence	Well-Differentiated NET N (%)	Poorly Differentiated NEC N (%)	Unknown/ambiguous Differentiation N (%)
Treatment 1	N = 21	N = 38	N = 8
TURBT	0	13 (34%)	0
Platinum-based therapy	2 (10%)	8 (21%)	3 (38%)
SSA	10 (48%)	1 (3%)	0
Resection	8 (38%)	4 (11%)	3 (38%)
Immunotherapy	0	6 (16%)	1 (13%)
Targeted agents	1 (5%)	2 (5%)	0
Treatment 2	N = 18	N = 26	N = 7
Targeted agents	5 (28%)	1 (4%)	0
Liver directed therapy	3 (17%)	0	0
Radiation	2 (11%)	2 (8%)	2 (29%)
Temozolomide ± Capecitabine	2 (11%)	0	0
Resection	1 (6%)	6 (23%)	1 (14%)
Platinum-based therapy	0	11 (42%)	1 (14%)
Immunotherapy	1 (6%)	2 (8%)	0
SSA	2 (11%)	1 (4%)	2 (29%)
Treatment 3	N = 17	N = 14	N = 6
Liver directed therapy	2 (12%)	0	0
Resection	6 (35%)	1 (7%)	1 (17%)
SSA	2 (12%)	0	1 (17%)
Immunotherapy	0	3 (21%)	0
Platinum-based therapy	0	4 (29%)	1 (17%)
Targeted agents	5 (29%)	2 (14%)	1 (17%)
Treatment 4	N = 12	N = 11	N = 4
Immunotherapy	0	3 (27%)	0
Targeted agents	3 (25%)	2 (18%)	1 (25%)
SSA	2 (17%)	0	0
Resection	2 (17%)	0	0
Temozolomide ± Capecitabine	1 (8%)	2 (18%)	2 (50%)
PRRT	2 (17%)	0	0
Treatment 5	N = 9	N = 6	N = 4
Topoisomerase inhibitors	0	2 (33%)	0
Targeted agents	3 (33%)	0	1 (25%)
Temozolomide ± Capecitabine	2 (22%)	0	1 (25%)
Liver directed therapy	1 (11%)	0	0
PRRT	1 (11%)	0	0

^aMetastatic disease included stage IV disease at diagnosis or pts developed stage IV disease ≥ 6 months from UNENs diagnosis